Clarithromycin - a common antibiotic used for treating respiratory tract infections was found to be associated with a higher risk of heart problems, says study published in BMJ.
The authors say their findings require confirmation, but add to a growing body of evidence suggesting a possible link between long term cardiovascular risks and certain antibiotics, known as macrolides.
Diet, Lifestyle and Heart Disease
The correlation between diet, lifestyle and heart disease. The importance of balanced diet life style and exercise for controlling heart disease.
Advertisement
Clarithromycin is often used to treat a sudden increase in symptoms for the progressive lung disease COPD - and in community acquired pneumonia - two of the most frequent causes of hospital admission in the UK. Previous studies have suggested that cardiovascular events, such as heart failure, heart rhythm problems, or sudden cardiac death, may be increased during treatment with clarithromycin, but the long term effects are still unclear.
So a team of UK researchers, led by the University of Dundee, set out to examine this association in more detail. They analysed data on 1,343 patients admitted to hospital with acute exacerbations of COPD and 1,631 patients admitted with community acquired pneumonia.
![Quiz on Antibiotics]( "Quiz on Antibiotics")
Your doctor may suggest antibiotics at the first sight of an infection, but how much do you really know about these wonder drugs? Test yourself.
They classified all patients who received at least one dose of clarithromycin during their hospital visit as macrolide users and compared them with patients who did not receive any macrolide antibiotics during their visit. Over one year, 268 COPD patients and 171 pneumonia patients were admitted to hospital as a result of a cardiovascular event.
In all, after allowing for other factors, 73/281 (26%) of the patients prescribed clarithromycin during acute exacerbations of COPD had at least one cardiovascular event over the next year compared to 195/1062 (18%) of the patients who didn't get this antibiotic (Hazard Ratio 1.50 - where Hazard Ratio is a measure of the number of events per unit time divided by the number of people at risk of the event).
In the same group the Hazard Ratio for acute coronary syndrome (severe angina attacks or heart attacks) was 1.67. Among patients given clarithromycin for community acquired pneumonia, 123/980 (12%) had at least one cardiovascular event compared to 48/651 (7%) not on the drug (Hazard Ratio 1.68). There was no increased risk of acute coronary syndrome.
For COPD, a significant association was also found between clarithromycin use and cardiovascular mortality, but not all cause mortality. In contrast, for community acquired pneumonia, no association was found between clarithromycin use and cardiovascular mortality or all cause mortality.
Longer durations of clarithromycin use were associated with more cardiovascular events. However, use of other types of antibiotics, such as ß-lactams, showed no association, suggesting an effect specific to clarithromycin, say the authors.
For COPD, a significant association was also found between clarithromycin use and cardiovascular mortality, but not all cause mortality. In contrast, for community acquired pneumonia, no association was found between clarithromycin use and cardiovascular mortality or all cause mortality.
Longer durations of clarithromycin use were associated with more cardiovascular events. However, use of other types of antibiotics, such as ß-lactams, showed no association, suggesting an effect specific to clarithromycin, say the authors.
Overall, the results suggest that there will be an additional cardiovascular event for every eight patients given clarithromycin compared to patients not given the drug (or one in 11 for pneumonia).
The data also suggest that the increased risk may persist beyond the time when clarithromycin is stopped. This could be due to clarithromycin's effect on the body's inflammatory process in patients with chronic lung conditions.
The authors conclude that the findings "need to be validated in other datasets before recommendations to change practice can be made."
Source: Eurekalert
Quiz on Antibiotics
Your doctor may suggest antibiotics at the first sight of an infection, but how much do you really know about these wonder drugs? Test yourself.
Advertisement
They classified all patients who received at least one dose of clarithromycin during their hospital visit as macrolide users and compared them with patients who did not receive any macrolide antibiotics during their visit. Over one year, 268 COPD patients and 171 pneumonia patients were admitted to hospital as a result of a cardiovascular event.
In all, after allowing for other factors, 73/281 (26%) of the patients prescribed clarithromycin during acute exacerbations of COPD had at least one cardiovascular event over the next year compared to 195/1062 (18%) of the patients who didn't get this antibiotic (Hazard Ratio 1.50 - where Hazard Ratio is a measure of the number of events per unit time divided by the number of people at risk of the event).
In the same group the Hazard Ratio for acute coronary syndrome (severe angina attacks or heart attacks) was 1.67. Among patients given clarithromycin for community acquired pneumonia, 123/980 (12%) had at least one cardiovascular event compared to 48/651 (7%) not on the drug (Hazard Ratio 1.68). There was no increased risk of acute coronary syndrome.
For COPD, a significant association was also found between clarithromycin use and cardiovascular mortality, but not all cause mortality. In contrast, for community acquired pneumonia, no association was found between clarithromycin use and cardiovascular mortality or all cause mortality.
Longer durations of clarithromycin use were associated with more cardiovascular events. However, use of other types of antibiotics, such as ß-lactams, showed no association, suggesting an effect specific to clarithromycin, say the authors.
For COPD, a significant association was also found between clarithromycin use and cardiovascular mortality, but not all cause mortality. In contrast, for community acquired pneumonia, no association was found between clarithromycin use and cardiovascular mortality or all cause mortality.
Longer durations of clarithromycin use were associated with more cardiovascular events. However, use of other types of antibiotics, such as ß-lactams, showed no association, suggesting an effect specific to clarithromycin, say the authors.
Overall, the results suggest that there will be an additional cardiovascular event for every eight patients given clarithromycin compared to patients not given the drug (or one in 11 for pneumonia).
The data also suggest that the increased risk may persist beyond the time when clarithromycin is stopped. This could be due to clarithromycin's effect on the body's inflammatory process in patients with chronic lung conditions.
The authors conclude that the findings "need to be validated in other datasets before recommendations to change practice can be made."
Source: Eurekalert
The Lungs - Animation
The lungs are our organs of respiration. It is within these, that exchange of gases takes place.
Advertisement
 Tree Tea Oil Does Not Increase Resistance to AntibioticsA recent research has reported that tea tree oil, commonly used in cosmetic products, does not increase the resistance of bacteria to other antibiotics. | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
Women using hormonal contraception, along with their healthcare providers, should explore alternative pain relief options instead of NSAIDs.
